Pulmonology Medical News about Pulmonary Disease, Chronic Obstructive Arformoterol

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: A single-dose, multicenter, randomized, modified-blind, two-way crossover study
Clinical Therapeutics, 10/16/09

Panettieri Jr RA et al. – In these subjects with moderate to severe COPD, single–day administrations of ARF15 BID or ARF30 QD were associated with FEV1 responses over a period of 24 hours that were considered equivalent per the protocol definition employed in the present study. FEV1 improvement over 12 hours was greater for ARF30 QD after the morning dose and for ARF15 BID after the evening dose.

<< Previous
Budesonide/formoterol pressurized metered-dose inhaler: a guide...

Next >>
Exercise Capacity and Obstructive Sleep Apnea in Lean Subjects

Increased relative mortality in women with severe oxygen-dependent chronic obstructive pulmonary disease
Chest, 10/07/09 Relevance Score: 90%

Increased relative mortality in women with severe oxygen-dependent chronic obstructive pulmonary disease
Chest, 10/05/09 Relevance Score: 90%

Chronic Obstructive Pulmonary Disease
Internet Source, 10/30/09 Relevance Score: 89%

CAM and Respiratory Disease
Nutrition in Clinical Practice, 10/30/09 Relevance Score: 89%

The immediate effect of individual manipulation techniques on pulmonary function measures in persons with chronic obstructive pulmonary disease
Internet Source, 10/09/09 Relevance Score: 89%